Record Global Revenue
Global revenue for Q3 2024 reached a record $62.3 million, representing 18.1% reported growth and 17.6% constant currency growth.
Strong U.S. and International Performance
U.S. revenue was $51.2 million with 14.8% growth, and international revenue was $11.2 million with 35.7% reported and 32.8% constant currency growth.
New Product Launches
2024 saw 13 new product launches, including key products like the Phantom Fibula Nail System and a short stem tibia implant, driving significant excitement and adoption.
Improved Adjusted EBITDA
Adjusted EBITDA for Q3 2024 was a profit of $432,000, marking the first full quarter of positive adjusted EBITDA since the company's IPO in October 2021.
Increased Revenue Guidance
Full-year 2024 revenue guidance was increased to $252 million to $256 million, reflecting 16.5% to 18.3% growth.
Significant Free Cash Flow Improvement
Free cash flow improved by 69.5% compared to Q3 2023 and 54.7% sequentially from Q2 2024.